Literature DB >> 18694953

Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.

M Mar Rodríguez1, Carolina Serena, Marçal Mariné, F Javier Pastor, Josep Guarro.   

Abstract

In a murine model of disseminated zygomycosis, low doses of amphotericin B (0.3 mg/kg body weight/day) combined with posaconazole (40 mg/kg/day) prolonged survival and reduced tissue burden with respect to that of controls and that of both drugs administered alone. Results were similar to those obtained with amphotericin B given alone at 0.8 mg/kg/day.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18694953      PMCID： PMC2565887          DOI： 10.1128/AAC.00628-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.

Authors:  V Rickerts; J Atta; S Herrmann; V Jacobi; E Lambrecht; R Bialek; G Just-Nübling
Journal:  Mycoses       Date:  2006       Impact factor: 4.377

5.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 6.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

7.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice.

Authors:  Javier Capilla; Carolina Serena; F Javier Pastor; Montserrat Ortoneda; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 9.  Treatment of zygomycosis: current and new options.

Authors:  Thomas R Rogers
Journal:  J Antimicrob Chemother       Date:  2008-01       Impact factor: 5.790

10.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Authors:  Jo-Anne H van Burik; Roberta S Hare; Howard F Solomon; Michael L Corrado; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-02-21       Impact factor: 9.079
View more
  25 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

3.  Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.

Authors:  Livio Pagano; Oliver A Cornely; Alessandro Busca; Morena Caira; Simone Cesaro; Cristiana Gasbarrino; Corrado Girmenia; Werner J Heinz; Raoul Herbrecht; Cornelia Lass-Flörl; Annamaria Nosari; Leonardo Potenza; Zdenek Racil; Volker Rickerts; Donald C Sheppard; Arne Simon; Andrew J Ullmann; Caterina Giovanna Valentini; Jörg Janne Vehreschild; Anna Candoni; Maria J G T Vehreschild
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

4.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.

Authors:  Jeffrey D Jenks; Sharon L Reed; Danila Seidel; Philipp Koehler; Oliver A Cornely; Sanjay R Mehta; Martin Hoenigl
Journal:  Int J Antimicrob Agents       Date:  2018-08-09       Impact factor: 5.283

6.  Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.

Authors:  M Mar Rodríguez; F Javier Pastor; Deanna A Sutton; Enrique Calvo; Annette W Fothergill; Valentina Salas; Michael G Rinaldi; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

7.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

8.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

10.  Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.

Authors:  M Mar Rodríguez; Enrique Calvo; Marçal Mariné; F Javier Pastor; Joan Fernandez-Ballart; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.